GELNIQUE 3%
PeakNDATRANSDERMALGEL, METERED
Approved
Dec 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GELNIQUE 3% is a transdermal gel formulation of oxybutynin, an anticholinergic agent approved in 2011 for overactive bladder. The metered-dose gel delivers the active pharmaceutical ingredient through the skin, offering an alternative to oral formulations with potentially improved tolerability. It treats symptoms of overactive bladder including urgency, frequency, and urge incontinence.
Peak
Peak-stage product with moderate competitive pressure (30%) suggests stable revenue but requires defensive positioning against generics and alternative delivery mechanisms.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GELNIQUE 3% roles are concentrated in commercial and medical affairs as a peak-stage product requiring market defense and physician education. Limited job openings (0 linked) reflect stable mature product status with lower growth trajectory compared to launch-stage products.
Brand ManagerMedical Science Liaison
Worked on GELNIQUE 3% at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.